The Journal of Practical Medicine ›› 2021, Vol. 37 ›› Issue (3): 365-368.doi: 10.3969/j.issn.1006⁃5725.2021.03.018

• Drugs and Clinic Practice • Previous Articles     Next Articles

Effect and safety of chemotherapy⁃based PD⁃1 inhibitors in the treatment of advanced lung adenocarcino⁃ma

LI Xing，MA Li′na，CHENG Xiaozhen，CUI Ronghua，ZHANG Shubo
  

  1. Department of Oncology，Medicine，Affiliated Haikou Hospital of Xiangya Medical College，Central South University，Haikou 570208，China
  • Online:2021-02-10 Published:2021-02-10

Abstract:

Objective To investigate the effect and safety analysis of PD⁃1 inhibitors in the treatment of advanced lung adenocarcinoma. Methods 86 patients with advanced lung adenocarcinoma from August 2018 to July 2019 in our hospital were selected as the research object，and were randomly divided into the control group （46 cases）and an the observation group（40 cases）. The control group and observation group were given pemetrex Cypriot combined with cisplatin，while the observation group was additionally treated with PD1 inhibitors. The serum tumor marker levels，treatment effects，and incidence of adverse reactions，survival time were compared between the two groups. Results The objective remission rate（ORR）of the observation group was significantly higher than that of the control group（P < 0.05）. The PFS in the observation group was 9.3 months，and the median PFS in the control group was 5.3 months. 3 months after treatment，the CYFRA21⁃1 ，CEA level of the observation group compared with the control group was significantly lower（P < 0.05）. The incidence of fatigue，nausea，neu⁃ tropenia，and thrombocytopenia in the observation group were not significantly different from those in the control group（P > 0.05）. The incidence of rash，hypothyroidism in the observation group was higher than that in the control group，and the difference in the incidence of abnormal energy was statistically significant（P = 0.041）. Conclusion PD⁃1 inhibitors are effective and safe in advanced lung adenocarcinoma.

Key words: